Although GLP-1 mimetics have been given pharmacologically in the treatment of T2DM and obesity [2], an alternative would be to use agents which enhance endogenous GLP-1 production to harness similar benefits with potentially fewer adverse effects. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.